Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective

2020 ◽  
Author(s):  
John F. Kellie ◽  
John C. Tran ◽  
Wenying Jian ◽  
Barry Jones ◽  
John T. Mehl ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Clinical Studies ◽  
Therapeutic Protein ◽  
Intact Protein ◽  
Protein Mass ◽  
Protein Mass Spectrometry ◽  
Protein Quantitation ◽  
Preclinical And Clinical Studies

scholarly journals Intact protein mass spectrometry reveals intraspecies variations in venom composition of a local population of Vipera kaznakovi in Northeastern Turkey

2019 ◽  
Vol 199 ◽  
pp. 31-50 ◽  
Author(s):  
Daniel Petras ◽  
Benjamin-Florian Hempel ◽  
Bayram Göçmen ◽  
Mert Karis ◽  
Gareth Whiteley ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Local Population ◽  
Intact Protein ◽  
Protein Mass ◽  
Protein Mass Spectrometry ◽  
Venom Composition

Intact Protein Mass Spectrometry of Cell Culture Harvest Guides Cell Line Development for Trispecific Antibodies

2020 ◽  
Vol 92 (3) ◽  
pp. 2764-2769
Author(s):  
Fateme Tousi ◽  
Yan Jiang ◽  
Sharmila Sivendran ◽  
Yvonne Song ◽  
Susan Elliott ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Cell Culture ◽  
Cell Line ◽  
Intact Protein ◽  
Cell Line Development ◽  
Protein Mass ◽  
Protein Mass Spectrometry

scholarly journals VisioProt-MS: interactive 2D maps from intact protein mass spectrometry

2018 ◽  
Vol 35 (4) ◽  
pp. 679-681 ◽  
Author(s):  
Marie Locard-Paulet ◽  
Julien Parra ◽  
Renaud Albigot ◽  
Emmanuelle Mouton-Barbosa ◽  
Laurent Bardi ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Intact Protein ◽  
Protein Mass ◽  
Protein Mass Spectrometry

Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing

2020 ◽  
Vol 58 (6) ◽  
pp. 858-863 ◽  
Author(s):  
Dobrin Nedelkov ◽  
Yueming Hu
Keyword(s):  
Mass Spectrometry ◽  
Intact Protein ◽  
Clinical Implications ◽  
Clinical Testing ◽  
Protein Mass ◽  
Protein Mass Spectrometry ◽  
Apolipoprotein C ◽  
Complexity Cost ◽  
The Many ◽  
Clinical Measures

AbstractComplexity, cost, and content are three important factors that can impede translation of clinical protein mass spectrometry (MS) tests at a larger scale. Complexity stems from the many components/steps involved in bottom-up protein MS workflows, making them significantly more complicated than enzymatic immunoassays (EIA) that currently dominate clinical testing. This complexity inevitably leads to increased costs, which is detrimental in the price-competitive clinical marketplace. To successfully compete, new clinical protein MS tests need to offer something new and unique that EIAs cannot – a new content of proteoform detection. The preferred method for proteoform profiling is intact protein MS analysis, in which all proteins are measured as intact species thus allowing discovery of new proteoforms. To illustrate the importance of intact proteoform testing with MS and its potential clinical implications, we discuss here recent findings from multiple studies on the distribution of apolipoprotein C-III proteoforms and their correlations with key clinical measures of dyslipidemia. Such studies are only made possible with assays that are low in cost, avoid unnecessary complexity, and are unique in providing the content of proteoforms.

scholarly journals Fungal siderophore biosynthesis catalysed by an iterative nonribosomal peptide synthetase

2020 ◽  
Vol 11 (42) ◽  
pp. 11525-11530
Author(s):  
Yang Hai ◽  
Matthew Jenner ◽  
Yi Tang
Keyword(s):  
Mass Spectrometry ◽  
Assembly Line ◽  
Nonribosomal Peptide Synthetase ◽  
Intact Protein ◽  
Nonribosomal Peptide ◽  
Protein Mass ◽  
Siderophore Biosynthesis ◽  
Protein Mass Spectrometry ◽  
Peptide Synthetase

Snapshots of fungal siderophore biosynthesis on the biosynthetic assembly-line captured by intact protein mass-spectrometry.

Sign in / Sign up

Export Citation Format

Share Document